An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

HPV4 and HPV9 vaccines are indicated for the prevention of the following diseases associated with the HPV types contained in the vaccines: In females 9 to 45 years of age • Cervical, vulvar, vaginal cancers and pre-cancerous lesions • AGWs 4 |. UPDATED RECOMMENDATIONS ON HUMAN PAPILLOMAVIRUS (HPV) VACCINES: 9-VALENT HPV VACCINE 2-DOSE IMMUNIZATION SCHEDULE AND THE USE OF HPV VACCINES IN IMMUNOCOMP [...] In a 3-dose schedule, the minimum interval between the first and second doses of vaccine is 4 weeks, the minimum interval between the second and third doses of vaccine is 12 weeks and the minimum interval between the first and last doses in either a 2-dose or 3-dose schedule is 24 weeks. [...] This statement will: Review evidence for a 2-dose immunization schedule of the HPV9 vaccine, and provide recommendations; Summarise evidence from a recent NACI Literature Review on the use of HPV vaccines in immunocompromised populations, and provide recommendations for HPV vaccine use in these groups. [...] Preparations of HPV vaccines authorized for use in Canada Characteristics of the HPV vaccines currently authorized for use in Canada are summarized in Table 2. 10 |. UPDATED RECOMMENDATIONS ON HUMAN PAPILLOMAVIRUS (HPV) VACCINES: 9-VALENT HPV VACCINE 2-DOSE IMMUNIZATION SCHEDULE AND THE USE OF HPV VACCINES IN IMMUNOCOMPROMISED POPULATIONS Table 2. Comparison of HPV Vaccines Authorized for Use in C [...] If completion of the series with the same vaccine is not possible, the HPV2, HPV4 or HPV9 vaccine may be used to complete the series in females, and the HPV4 or HPV9 vaccine may be used to complete the series in males.